108 related articles for article (PubMed ID: 2936784)
21. Multicenter placebo-controlled evaluation of nomifensine treatment in depressed outpatients.
Feighner JP; Merideth CH; Claghorn JL
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):47-51. PubMed ID: 6370974
[TBL] [Abstract][Full Text] [Related]
22. [Cognitive disorders in the structure of endogenous depression in old age].
Iakovleva OB
Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(5):62-8. PubMed ID: 8585380
[TBL] [Abstract][Full Text] [Related]
23. The relationship between severity of depression, cognitive dysfunction, and age in medical inpatients.
Cavanaugh SA; Wettstein RM
Am J Psychiatry; 1983 Apr; 140(4):495-6. PubMed ID: 6837796
[No Abstract] [Full Text] [Related]
24. Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder.
Taneri Z; Köhler R
Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():57-61. PubMed ID: 2783700
[No Abstract] [Full Text] [Related]
25. [Controlled clinical trial of nomifensine in treatment of depression (author's transl)].
Zaccara G; Ferrara M; Ardito P
Riv Patol Nerv Ment; 1979; 100(3):111-20. PubMed ID: 400045
[TBL] [Abstract][Full Text] [Related]
26. Executive dysfunction in late-life depression.
Rajtar-Zembaty A; Sałakowski A; Rajtar-Zembaty J; Starowicz-Filip A
Psychiatr Pol; 2017 Aug; 51(4):705-718. PubMed ID: 28987059
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine.
Quadbeck H; Lehmann E; Tegeler J
Neuropsychobiology; 1984; 11(2):111-5. PubMed ID: 6384815
[TBL] [Abstract][Full Text] [Related]
28. Pooling 12 nomifensine studies for efficacy generalizability.
Gillings D; Grizzle J; Koch G; Rickels K; Amara I; Donelan M; Hardiman S; Nash R; Sollecito W; Stager W
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):78-84. PubMed ID: 6370982
[TBL] [Abstract][Full Text] [Related]
29. Six-month Follow-up of Cognitive Impairment and Depressive Symptoms in Late-onset Depression.
Wong MM; Chan CF; Li SW; Lau YM
East Asian Arch Psychiatry; 2015 Dec; 25(4):146-9. PubMed ID: 26764288
[TBL] [Abstract][Full Text] [Related]
30. Nomifensine: an antidepressant with a difference?
Ereshefsky L
Clin Pharm; 1985; 4(6):673-4. PubMed ID: 4075735
[No Abstract] [Full Text] [Related]
31. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study.
Schiff R; Bulpitt CJ; Wesnes KA; Rajkumar C
Psychoneuroendocrinology; 2005 May; 30(4):309-15. PubMed ID: 15694110
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of nomifensine, maprotiline and imipramine in a double-blind study of patients with endogenous depression].
Faltus F; Filip V; Karen P; Kolomazník M; Korínková V; Libiger J; Molcan J; Zapletálek M; Zizka V
Cesk Psychiatr; 1986 Apr; 82(2):131-8. PubMed ID: 3524870
[No Abstract] [Full Text] [Related]
33. Double-blind comparison of diclofensine with nomifensine in outpatients with dysphoric mood.
Funke HJ; Holtmann W; Ismail S; Jansen W; Leonhardt KF; Muth H; Omer LM; O'Connolly M; Ramm H
Pharmacopsychiatry; 1986 May; 19(3):120-3. PubMed ID: 3725890
[TBL] [Abstract][Full Text] [Related]
34. An overview of side effects and long-term experience with nomifensine from United States clinical trials.
Yakabow AL; Hardiman S; Nash RJ
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):96-101. PubMed ID: 6370985
[TBL] [Abstract][Full Text] [Related]
35. Double-blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients.
Georgia EH
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):43-6. PubMed ID: 6232263
[TBL] [Abstract][Full Text] [Related]
36. Depressive symptoms and cognitive decline.
Cervilla J
Br J Psychiatry; 2003 Apr; 182():364. PubMed ID: 12668417
[No Abstract] [Full Text] [Related]
37. Does education moderate neuropsychological impairment in late-life depression?
Bhalla RK; Butters MA; Zmuda MD; Seligman K; Mulsant BH; Pollock BG; Reynolds CF
Int J Geriatr Psychiatry; 2005 May; 20(5):413-7. PubMed ID: 15852438
[TBL] [Abstract][Full Text] [Related]
38. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine.
Nolen WA; van de Putte JJ; Dijken WA; Kamp JS; Blansjaar BA; Kramer HJ; Haffmans J
Acta Psychiatr Scand; 1988 Dec; 78(6):676-83. PubMed ID: 3146891
[TBL] [Abstract][Full Text] [Related]
39. A double-blind clinical trial of nomifensine vs. amitriptyline in depressed patients.
Cassano GB; Conti L; Massimetti G; Fornaro P; Levine J
Pharmacopsychiatria; 1982 May; 15(3):84-9. PubMed ID: 7100261
[TBL] [Abstract][Full Text] [Related]
40. [Clinical polymorphism of depression and cognitive deficit].
Bobrov AE; Kursakov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):19-24. PubMed ID: 25345626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
